Researchers have shown that two lab-developed and nasally-delivered peptides helped slow the spread of alpha-synuclein in mice. ‘If these results can be replicated in patients, it would be a remarkable advance in the treatment of devastating neurological disorders,’ says the lead author.
Click here for original story, Nasal drugs show promise for slowing Parkinson’s disease progression in lab study
Source: ScienceDaily